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A realist evaluation
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Abstract
Objectives: To explore how embedded patient and public involvement is within mainstream health research following
two decades of policy-driven work to underpin health research with patient and public involvement in England.
Methods: Realist evaluation using Normalization Process Theory as a programme theory to understand what enabled
patient and public involvement to be embedded as normal practice. Data were collected through a national scoping and
survey, and qualitative methods to track patient and public involvement processes and impact over time within 22
nationally funded research projects.
Results: In research studies that were able to create reciprocal working relationships and to embed patient and public
involvement this was contingent on: the purpose of patient and public involvement being clear; public contributors
reflecting research end-beneficiaries; researchers understanding the value of patient and public involvement; patient and
public involvement opportunities being provided throughout the research and ongoing evaluation of patient and public
involvement. Key contested areas included: whether to measure patient and public involvement impact; seeking public
contributors to maintain a balance between being research-aware and an outsider standpoint seen as ‘authentically’ lay;
scaling-up patient and public involvement embedded within a research infrastructure rather than risk token presence and
whether patient and public involvement can have a place within basic science.
Conclusions: While patient and public involvement can be well-integrated within all types of research, policy makers
should take account of tensions that must be navigated in balancing moral and methodological imperatives.
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Introduction
While patient and public involvement (PPI) in research
is increasing in many parts of the world,1 the United
Kingdom (UK) health research arena is recognised as
having led the way through its significant policy drive
to embed PPI within the national health research infra-
structure.2 PPI became a statutory part of the national
research governance framework in 2005 and is now
integral to the main UK health research funding
streams. Researchers are routinely required to show
how PPI has shaped their research proposal and its
delivery.
To establish PPI within a national research infra-
structure requires significant investment. Such resour-
ces are commonly justified by two main arguments.
First, alongside the democratic imperative, the moral
argument asserts that research conducted on people
without their input is unethical. The second argument
for PPI is methodological, that having PPI within a
research study will improve recruitment, impact and
outcomes.
Despite claims for impact, there is less evidence of the
actual processes or mechanisms that enable PPI to fulfil
its promises. Ten years after a PPI research infrastruc-
ture was created in the UK, it is also unclear whether
and how PPI has become embedded within the health
research environment. This paper presents findings from
a realist evaluation of PPI in health research in England3
to explore how PPI becomes integrated within clinical
research and what actions enable this.
The terms ‘participation’, ‘engagement’ and
‘involvement’ are often used interchangeably to capture
what PPI entails. For the purposes of this paper, we use
the following definitions: ‘involvement’ being active
involvement of public members in advising on scope,
direction and conduct of research and research organ-
izations; ‘engagement’ involving the provision and dis-
semination of information and knowledge about
research and ‘participation’ denoting when people
take part in a research study to provide its data.2
Methods
The Research into Patient and Public Involvement: A
Realist Evaluation (RAPPORT) study3 was conducted
in England from 2011 to 2013 and was approved by the
National Research Ethics Service Committee East
Midlands – Nottingham 1 Research Ethics
Committee (reference 11/EM/0332).
Previous evaluations of PPI have been criticised for
using designs incapable of exploring contextual factors
and mechanisms that enable or inhibit PPI process and
impact.4 We adopted a realist evaluative design5 to
develop a theory-driven account of what enables PPI
to be integrated as normal practice, and under what
circumstances, in terms of research type and setting.
The RAPPORT study design is illustrated in
Figure 1. Data were collected through two main meth-
ods. First, a national scoping exercise and survey was
conducted with investigators of studies adopted by the
UK Clinical Research Network, detailed elsewhere.6
The results were used to select 22 nationally funded
research projects as case studies in which to explore
PPI processes and impact. Case studies were followed
up over 18 months, through semi-structured interviews
(initial and regular follow-up) and documentary anal-
ysis (for example, notes from team meetings).
As we were interested in how PPI becomes embed-
ded within clinical research, Normalization Process
Theory8 provided an explanatory theory to inform
the development of a PPI specific programme theory
about how PPI has become embedded (or not) as
normal practice within health research.9
To capture a broad range of study designs, popula-
tions and topic areas, we purposively focused our data
collection on six diverse topic areas: arthritis; cystic
fibrosis; dementia; diabetes; intellectual and
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Figure 1. RAPPORT study design (adapted from Pawson and Tilley5 and Hewitt et al.7).
RAPPORT: Research into Patient and Public Involvement: A Realist Evaluation. CMO: context, mechanism and outcome.
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developmental disabilities and public health (Table 1).
This ensured that we included studies with different
population ages, accessibility challenges and history
of PPI. Cystic fibrosis studies were more likely to be
laboratory-based or have a biomedical focus, whereas
the other topic areas tended to involve a range of
designs and sample size.
Within the case studies, we interviewed 64 research-
ers, 48 public contributors, 7 PPI coordinators and 10
representatives from funding organizations and UK
Clinical Research topic networks (n¼ 129). We also
analysed 278 documents. We were more successful in
recruiting interviewees from some topic areas than
others, and case studies differed in providing us
access to their documents.
We used Normalization Process Theory to provide
an initial coding frame for the analysis of the interview
data and documents.10 We followed a stepped
approach to data analysis11 (Figure 2) and the study
itself was underpinned by PPI as reported elsewhere.12
The use of Normalization Process Theory radar
plots10 and realist evaluation summaries helped us
understand changes in PPI processes over time within
case studies. Regular research team meetings were held
to compare data across the case studies and discuss
emerging context, mechanism and outcome (CMO)
configurations. These CMO configurations were tested
across the data set and rejected, accepted, or refined.
Candidate CMO configurations were further refined
through discussion with case study participants,
Table 1. RAPPORT case studies.
Topic Study design Funder Documents
Interview
participants
Dementia Basic science involving
humans
National Institute of Health
Research (NIHR)
38 3
Dementia Clinical Trial of an
Investigational Medicinal
Product (CTIMP)
NIHR 5 4
Diabetes CTIMP NIHR 19 4
Diabetes Trial, cohort, qualitative NIHR 13 9
Diabetes Mixed qualitative/quantitative NIHR 8 4
Diabetes Qualitative Non-commercial 1 3
Diabetes Randomized Controlled Trial
(RCT) to compare
intervention
NIHR 11 4
Diabetes Basic science involving
humans
Charity 16 4
Diabetes Genetic epidemiology Charity 9 3
Diabetes Intervention (mixed quantita-
tive/qualitative)
Charity 4 10
Arthritis CTIMP Charity 3 4
Arthritis Research database Research Council/Charity 0 4
Arthritis Cohort Charity 3 9
Arthritis Qualitative methods Research Council 16 4
Public health RCT to compare
intervention
NIHR 5 4
Public health RCT to compare
intervention
NIHR 27 6
Public health Survey/qualitative Charity 19 13
Public health RCT to compare
intervention
NIHR 12 6
Intellectual and developmental
disabilities
Questionnaire NIHR 17 4
Intellectual and developmental
disabilities
RCT to compare
intervention
NIHR 9 7
Intellectual and developmental
disabilities
Systematic review NIHR 22 6
Cystic fibrosis CTIMP NIHR/Research Council 21 4
Total 278 119
RAPPORT: Research into Patient and Public Involvement: A Realist Evaluation.
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stakeholder reference groups made up of public contrib-
utors, and the RAPPORT independent advisory group.
Finally, the configurations were presented at four
regional events in England for refinement.
Results
We identified six CMO configurations and salient
actions13 that could explain what enabled PPI integra-
tion within the case studies.
Salient action 1: a clear purpose, role and
structure for PPI are ensured
A clear structure and understanding of the different
roles was required if PPI was to be seen as a different
way of working with patients and the public.
Requirements included an identified person to coordi-
nate PPI, but also the whole team being supportive of
PPI, with the work required for PPI being appropriate-
ly allocated. Providing skills, continued support and
trust in each other’s input were also key mechanisms.
This salient action was heavily influenced by the
non-negotiable requirement of UK research funders
that grant applications detail how PPI had contributed
to the proposal and would be operationalised within
the project. Many researchers had engaged with PPI
because they ‘had to’ to obtain funding. There were
differences between the main funding bodies on how
they prioritised and understood PPI. The funding pro-
grammes and management organizations of the
English National Institute for Health Research
1
• Independent coding by 5 team members
• Deductive using a Normalization Process Theory informed framework, and inductive to 
capture unforeseen themes
2
• Team meetings to discuss coding, address inconsistencies, and refine collective understanding 
of coding framework
• All coded data from interviews & documents collated for each case study using NVivo 9 
(QSR International, Warrington, UK)
3
• Data generated through interview were triangulated (including with study documents) to 
corroborate, elaborate, contradict or complement other data in order to interpret PPI processes 
and identify initial CMO configurations
• An initial summary of the Normalization Process Theory  analysis were then written for each 
case study and shared within the team to check consistency in the usage of coding categories
4
• The Economic and Social Research Council-funded web-based Normalization Process 
Theory toolkit 10 was used to develop radar plots for each case study. 
• These plots provided a temporal snapshot: a visual representation of the embeddedness of PPI 
in each case study 
5
• CMO configurations further refined for each case study, and then across all case studies
• CMO configurations used to identify salient actions leading to integration of PPI within case 
studies
Figure 2. Approach to analysis.
Wilson et al. 101
(NIHR) suggested that PPI impact should mainly be
seen from the methodological perspective, with PPI as
a way of improving research quality.
It [PPI], you know, is likely to improve recruitment. It
makes sure that it meets patient needs so that when it
gets out the other end into the implementation phase it
can actually have a possibility of having impact.
(Funder, NIHR)
In contrast, the large charitable funders often priori-
tised the moral imperative for PPI.
. . .we get our money from the public, from people with
the condition, so it’s really important that we include
viewpoints of people with the condition in our decision.
(Funder, Charity)
This initial funder-led coercion could be gradually
transformed into research team enthusiasm with the
positive impact of PPI. Funders spoke of a ‘sea-
change’ and some attributed a perceived improvement
of the quality of funding applications to growing PPI
contributions over the past 10 years.
The growth of PPI-related activity within funding
organizations had also brought about what one respon-
dent described as ‘industrial scale PPI’, seeming per-
haps at odds with the person-centred ethos of the
moral perspective of PPI. One consequence of this
formal PPI activity was the need to have people respon-
sible for coordination and continuity of PPI within
research. This had created a new role with a focused
responsibility for coordinating PPI. This role was often
challenging and demanded much effort, particularly if
dealing with large numbers of public contributors
through email or social media.
For research teams without dedicated PPI support,
access to an external pre-existing PPI group was an
enabler. With the drive towards PPI within the NIHR
infrastructure, topic-specific PPI panels had devel-
oped. Some researchers stated a preference for this
outsourced approach, suggesting it provided access
to a wider, more representative group, than the
‘usual suspects’ who were part of more local groups.
In contrast to working with an ‘in house’ group, the
interaction between the outsourced PPI panel and
research team tended to be for a single task; for exam-
ple, reviewing patient recruitment literature. While the
purpose and role for PPI was very clear in these cir-
cumstances, it also limited PPI impact to discrete
stages of the research process. In contrast, studies
with embedded PPI extended impact to, for example,
dissemination and identification of further research
priorities.
Salient action 2: active recruitment of public
contributors who reflect the diversity of a study
population
Researchers and funders acknowledged that to ensure
public involvement that reflected the defined research
study population posed a significant challenge. While
training in community engagement was helpful, study
teams located within the study population (for exam-
ple, clinical study teams) found it easier to recruit
public contributors. However, we found unintended
consequences of this approach to PPI recruitment,
with evidence of some merging of roles between being
study participant and also of being asked to advise the
study team. This dual role provided helpful consumer
feedback (for example, how the process of data collec-
tion was experienced) and could work well, but was
potentially problematic if participant and advisor
roles were blurred. Patients undertaking this dual role
were further confused when the investigator was also
their clinician; reporting it was difficult to remember
whether they were talking to the investigator as a par-
ticipant, patient or advisor.
You have to switch your hat and say ‘Look I’m not a
patient expert today, I’m a patient of yours and I want
you just to look at my illness and not discuss any other
research’. (Public contributor)
We also found examples of a single public contributor
acting as a link to the broader community. Frequently,
these people were recruited from charities that served
the study population. This worked well when the single
representative had strong links with the relevant com-
munity and acted as a two-way conduit between the
research team and community. However, recompense
for their time was sometimes an issue, particularly
when the PPI work impinged on other roles they had
within the charity.
Salient action 3: whole team engagement with PPI
For this action to be achieved, and despite new roles
being created, all researchers in the team needed none-
theless to engage with PPI. While having someone in
the research team responsible for PPI was important,
not having senior researchers engaged could lead to
tokenistic PPI. We found that the need to explain tech-
nical aspects of the research to public contributors had
also increased engagement with PPI throughout the
research team.
In 2014, producing a plain English summary of a
research project became a mandatory part of the appli-
cation for NIHR funding. Researchers reported being
initially challenged by this, but also described how
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working with public contributors had helped, again
supporting a visible positive impact of PPI. Having
the ability to write a publicly accessible explanation
of a research study was identified by senior researchers
as a transferable skill useful across their range of work.
When there was whole team engagement, recognizing
the full impact of PPI within projects was also more
likely through a shared narrative.
Salient action 4: mutual understanding and trust
Strong relationships were found to be fundamental to
PPI and these are predicated on a shared understand-
ing of what PPI is. There was some evidence that
researchers, and in particular, newer researchers, did
not fully understand the difference between patients
participating in research as a ‘subject’, and being
involved as advisors. The more junior researchers had
often joined a study only once it was funded and
received minimal training on PPI as part of their gen-
eral research education. In contrast, more senior
researchers understood the concept of PPI because of
the discipline of meeting funding requirements and
having been involved in applying for funding.
Trust also underpinned relationships in PPI and was
seen by researchers as essential for the smooth running
of the study. For public contributors, trust was created
when they felt valued. This sense of value was enhanced
if there was explicit appreciation by the research team
of their input, but especially if the relationship was
ongoing, ensuring that even at the end of the study
there was feedback given on how their input had influ-
enced the study. To this end, the PPI arena (its physical
setting, social context, and formality) where their input
was aired, needed careful facilitation. In more formal
settings, such as trial steering committees, public con-
tributors needed a skilled chairperson who ensured that
their contributions were made within an equitable envi-
ronment where all perspectives and needs were recog-
nized and valued.
Trust was also engendered by a sense that there was
fair reimbursement of PPI time. All case studies reim-
bursed for ‘out of pocket’ expenses; however, reimburs-
ing for time varied. Complexities around payment to
people while they were in receipt of social welfare was
raised as one significant issue, but some public contrib-
utors expressed unhappiness with the level of payment:
. . .people just make an assumption, oh they’re patients,
we won’t need to pay them. And you know our time in
our life is just as . . . important as a researcher’s.. . .
(Public contributor)
While shared understanding and feeling valued were
the foundations of relationships in PPI, the process of
building and sustaining relationships needed nurturing
over time. Only 19% (n¼ 9) of public contributors we
interviewed were working with researchers they had not
met or worked with before. Public contributors who
were known to the team were actively recruited to
new studies, bypassing the initial time required to
establish the working relationship. Sustained engage-
ment was also enabled by PPI groups being attached
to research centres.
Salient action 5: opportunities for PPI throughout
the research process
It was common for public contributors to be involved
throughout the research process within applied health
research. However, some researchers did question
whether this broad involvement was possible in basic
science studies and had the potential to ‘jeopardize the
research’ through a lack of technical understanding.
There were examples where PPI had worked well in
basic science research, including involvement in fund-
ing panels, and prioritizing studies for access to a tissue
bank database. However, this type of involvement in
basic science research required a dedicated facilitator
and the resources to support this. For studies of any
type without this level of support, public contributor
involvement was most marked during project set-up
but tailed off during recruitment phases when research
teams had intense periods of work and hence less
capacity to work with public contributors. Some
public contributors described ‘losing contact’ with the
project after extensive involvement during proposal
development and study set-up.
To ensure involvement at all stages of the research
cycle and as a way of addressing power differentials, it
is increasingly common for a member of the public to
be a co-applicant on a research grant application. For
example, the NIHR application process allows for a
‘lay’ co-applicant’s CV to be submitted alongside
those of the professional members of the research
team. However, there were some concerns from
laboratory-based scientists that having a lay co-
applicant was now seen as the ‘gold standard’, and
grants without one were seen to be less likely to suc-
ceed. These researchers felt that it would be very diffi-
cult to have a ‘non-scientist’ who would be able to be
fully engaged in the project.
Salient action 6: reflection, appraisal and
evaluation of PPI
We found that ongoing evaluation was necessary for
PPI integration as processes were modified to address
any issues. However, only two of the case studies were
systematically appraising PPI in their studies.
Wilson et al. 103
There were two reasons why studies did not evaluate
their PPI. Some questioned why focus only on PPI and
not the research process as a whole, and others identi-
fied the lack of readily available heuristic tools to sup-
port evaluation. However, many case studies did
routinely record PPI activities.
The need for robust PPI evaluation to know whether
it had an impact or not was seen as the ‘holy grail’ by
some researchers. There was also some debate on what
outcomes were being evaluated: PPI impact on the
research study outcome (for example, recruitment of
participants), or outcomes for researchers and PPI con-
tributors themselves? A number of researchers com-
mented on the impact of PPI in making them
reappraise the way they viewed an issue, and how
they related to the public. Public contributors frequent-
ly reported improved self-worth, increased health
knowledge and respite from caring roles, as the person-
al impact of undertaking a PPI role.
Barriers to normalizing PPI
While there was a direct relationship between the six
salient actions and how integrated PPI was within a
study, we also found a number of barriers to normal-
izing PPI. In global comparisons, PPI in UK health
research can be seen as the most heavily shaped by
the mainstream funders’ requiring PPI. Within
RAPPORT and other studies,14 the influence of fun-
ders was seen to be clearly shaped by values which
reflected a dichotomy between primarily methodologi-
cal and primarily moral imperatives for PPI. This
presents us with two discrete lenses through which to
view barriers to PPI integration and the ongoing debate
influencing how PPI may be embedded in health
research.
First, there are disagreements between those who see
developing tools to measure the impact of PPI as vital
within a resource-constrained system, and those who
see attempts to measure PPI impact as being at odds
with understanding PPI as a moral right and process.15
While the scientific community expects robust evidence
of the effectiveness of PPI, its complexity as a phenom-
enon makes it difficult to develop validated tools that
can provide broadly meaningful evidence.4,16 One chal-
lenge is to accommodate the multiple perspectives
involved, while acknowledging that these will influence
what may be identified as important to evaluate.17
Some call for the impact of PPI not just to be seen as
confined to the research outcomes but also to ways in
which it has changed the perspectives of researchers4
and public contributors.18 Rose19 critiques current
attempts at evaluating PPI for limiting evidence pre-
sented to descriptive case studies, which largely exclude
information on impact more relevant for assessing how
PPI changed the knowledge produced and its conse-
quent impact on the ultimate research beneficiaries.
Nevertheless, we found studies, which had embedded
PPI, were matching their evaluation approach with the
aims and purpose of PPI within that particular study,
as endorsed by Edelman and Barron.15 Understanding
how values shape the PPI purpose within a study, and
so affect how PPI should be measured or evaluated,
appears to be a prerequisite of transparency in any
adequate evaluative approach.20
A second contested area in PPI is how to find ‘the
right people’ to be public contributors. Public contrib-
utors have mainly been drawn from the well-educated,
retired and affluent,21 and are so less likely to represent
under-served populations. Some social anthropological
perspectives would define the challenge as to find public
contributors whose views authentically reflect their
insider knowledge of the study population.22
However, this insider status can pose problems, not
least because insiders from any community are still
unlikely to be a homogenous group, and they will
have their own diverse agendas not necessarily reflect-
ing the range of views of the broader study popula-
tion.22 Whether any public contributor can speak for
an entire study population must therefore be debat-
able.23 However, others argue from a consumerist per-
spective that even without complete representativeness,
at least some alternative perspectives will be voiced.24
Thus, recognizing the problem of representativeness
informs a current emphasis on recruiting more diverse
public contributors.15 The RAPPORT findings found
that pre-existing relationships, which take time to
develop, will encourage trust between researchers and
public contributors. Timescales are often short for car-
rying out funded research, so it is unsurprising that
most research teams within RAPPORT recruited
patient and public contributors already known to
them. However, there was evidence that this called
for some teams to carry out a delicate balancing act
in ensuring that the public involved had enough
(research) knowledge to be able to contribute in a
way researchers felt was useful, but not so much
(research) knowledge that they lost their distinct per-
spective and became research team insiders.
Maintaining this fine line is reported elsewhere25,26
and represents a fundamental conundrum of PPI:
maintaining a perspective as an insider (to study pop-
ulation) and also as an outsider (to research team) over
a study’s lifetime.
Within the case studies, we found some evidence
that PPI was being ‘procured’ from external provider
oganizations with whom the research team had little
other engagement. The UK policy imperative for PPI
in research has led to a rapid scaling-up, perhaps indi-
cating a move towards an ‘involvement industry’23
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characterised by commodification and standardization.
A commodity can have both use and exchange values
in transactions and PPI can be described as being ‘pur-
chased’ through some exchanges of values which can
improve the quality of research directly experienced
and in its wider applications.15,26 Commodification in
health care has been extensively critiqued as character-
izing depersonalization and bureaucratic control.27
However, Timmermans and Almeling27 argue that
commodification in the health care arena, rather than
informal ad hoc arrangements, can be more effective in
advancing important goals. Thus, it is not commodifi-
cation as such that is the problem, but rather, the way
it happens. Commodification may, equally, be interre-
lated with altruism and so engender new ideas and
awareness. In those case studies exemplifying embed-
ded PPI, a transaction was maintained between
researchers and public contributors through experien-
tial knowledge being treated as having value, and so
facilitating reciprocity in terms of increasing public
contributors’ self-worth alongside any monetary
exchange.
Some suggest that requiring PPI at every research
stage irrespective of whether the research focus is basic
science or applied, or its stage of development, is a
tyranny.26 We found in RAPPORT that basic science
studies were finding unexpected benefits from PPI, and
our interviews with funders revealed that after hesitant
implementation, public involvement in ‘blue skies’
research funding committees had been less challenging
than anticipated, bringing benefits such as more critical
appraisal of the likely usefulness of the end product of
translational research. This contradicts findings in the
van Bekkum and Hilton14 study of UK research fund-
ing bodies’ views on PPI where some funders view PPI
as unnecessary in ‘high-level science’. Those less critical
of PPI in all health research still caution that PPI may
at least be more challenging in basic science,28 and that
levels of PPI needed will vary between topics and sit-
uations.29 Nevertheless, Callard et al.30 call for PPI to
be reconceptualised within all stages of translational
research. They warn that restricting involvement to
latter stages, concerned only with improving recruit-
ment to trials and to disseminating findings risks the
research community producing interventions and prod-
ucts not fit for purpose, so that ethical concerns around
new research areas, such as biomarkers, will not be
interrogated, and omit patient and public potentially
valuable contributions to early stages of the research
process. As in considering commodification, we argue
that the problem is not about involving public contrib-
utors at all stages and types of research, but that it is
the less robust processes of involvement that more
often cause issues.
Discussion
Alongside a growing body of evidence is 20 years’ expe-
rience of attempts to embed PPI in UK health research,
which in the past decade has been underpinned by a
well-resourced infrastructure and dedicated organiza-
tion (INVOLVE) (http://www.invo.org.uk/) to support
PPI within the NIHR.
The NIHR commissioned a review of the state of
PPI in research,15 which informed the INVOLVE deci-
sion to focus on three priorities. The first priority is to
encourage more diversity, equity and inclusion. The
second is to develop support, capacity building and
learning and development for both public contributors
and the research community. The third is community,
network and partnership building. These priorities can
be informed by the RAPPORT findings which also
shed light on key areas of debate for policy makers to
consider. These include maintaining a balance between
the moral and methodological imperatives in evaluat-
ing PPI; seeking the most appropriate public contrib-
utors and how best to harness PPI skills and
relationships developed over time; ensuring adequate
resources and scale in PPI to support research whilst
avoiding impersonally ‘industrializing’ PPI activities
and finally, enabling optimal PPI contributions at all
stages of research without adversely affecting research
outcomes. Tensions are to be expected in PPI, but
working through them in partnership can fuel novel
research synergies.
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